title: Lung cancer after treatment for non-Hodgkin lymphoma.
abstract: OBJECTIVE
  Because of the improvement in treatment and survival of patients with lymphoma, late sequelae, including secondary cancers have been extensively studied. Lung cancer is one of the two most common solid tumors after Hodgkin's disease but fewer studies have been published about lung cancer after non-Hodgkin lymphoma (NHL).
  
  
  METHODS
  Over the last five years at our Institution we have observed 16 patients, 13 male and 3 female, with a mean age of 61 years, previously treated for NHL and lung cancer. Median latency between NHL and lung cancer was 7 years. In 6 patients (37.5%) the latency period was shorter than 5 years and 3 of them developed lung cancer within 2 years after the end of NHL therapy.
  
  
  RESULTS
  Ten patients underwent lung complete resection. Two, 3 and 5 year survival rate was respectively 52.7%, 26.3% and 13%. In contrast, the median survival of non surgical patients was 9 months. Comparison of survival between surgical and non-surgical group demonstrated a statistically significant better survival for surgically treated patients (P<0.04).
  
  
  CONCLUSIONS
  Surgery can improve survival in patients with history of NHL and lung cancer. Early diagnosis and treatment is crucial. NHL survivors should undergo careful follow-up and surveillance for secondary malignancy.
authors.affiliation: Department of Thoracic Surgery, University of Rome, La Sapienza, Rome, Italy. tiziano.degiacomo@tin.it
authors.forename: T
authors.initials: T
authors.lastname: De Giacomo
authors.forename: M
authors.initials: M
authors.lastname: Martelli
authors.forename: F
authors.initials: F
authors.lastname: Venuta
authors.forename: M
authors.initials: M
authors.lastname: Anile
authors.forename: D
authors.initials: D
authors.lastname: Diso
authors.forename: M
authors.initials: M
authors.lastname: Di Stasio
authors.forename: E A
authors.initials: EA
authors.lastname: Rendina
authors.forename: G F
authors.initials: GF
authors.lastname: Coloni
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000601:surgery; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008168:Lung / Q000473:pathology; D008175:Lung Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000601:surgery / Q000628:therapy; D008297:Male; D008481:Mediastinoscopy; D008875:Middle Aged; D009367:Neoplasm Staging; D016609:Neoplasms, Second Primary; D018358:Neuroendocrine Tumors / Q000401:mortality / Q000473:pathology / Q000601:surgery; D011013:Pneumonectomy; D011379:Prognosis; D013902:Radiography, Thoracic; D016019:Survival Analysis; D013997:Time Factors; D014057:Tomography, X-Ray Computed